Treatment of Abnormal Left Ventricular Wall Thickness

Diagnostic Workup to Guide Treatment

• The European Society of Cardiology recommends measuring maximum LV wall thickness at all segments from base to apex using echocardiography or CMR, with particular attention to anterolateral wall and apex where hypertrophy may be missed 1, 3
• The American College of Cardiology suggests obtaining 12-lead ECG looking for LVH voltage criteria, ST-T wave abnormalities, pathological Q-waves, or conduction abnormalities that suggest specific etiologies 1, 2
• The European Heart Journal recommends performing 48-hour ambulatory ECG monitoring to detect atrial and ventricular arrhythmias that impact risk stratification and treatment decisions 1
• Assessing for LV outflow tract obstruction using continuous wave Doppler at rest and with provocation is indicated, defining obstruction as gradient ≥30 mmHg and hemodynamically significant as ≥50 mmHg 1, 4

Treatment Based on Etiology

Hypertrophic Cardiomyopathy

• The European Society of Cardiology recommends first-line pharmacologic therapy with beta-blockers or verapamil for symptomatic patients with obstructive HCM, titrating to maximum tolerated doses before considering invasive therapy 1, 4
• Septal reduction therapy is indicated for patients with severe symptoms despite maximum medical therapy and resting or provocable gradient ≥50 mmHg 1
• Medical management focuses on symptom control with beta-blockers or verapamil for angina, dyspnea, or palpitations in non-obstructive HCM 1, 4

Hypertensive Heart Disease

• The European Society of Cardiology recommends aggressive BP control targeting systolic BP <130 mmHg, with reassessment of LV mass index after 6-12 months to document regression 5
• Calculating LV mass index and relative wall thickness is essential for diagnosis and monitoring 8
• Assessing diastolic function as E/e' ratio is predictive of primary cardiac events in uncomplicated hypertensive patients 8

Athlete's Heart

• The European Society of Cardiology states that no treatment is required if confirmed as physiologic adaptation 6, 7
• A detraining period of 3 months can confirm diagnosis if wall thickness regresses 6

Infiltrative/Storage Diseases

• Disease-specific therapy based on underlying condition is recommended, such as enzyme replacement for Fabry disease or treatment of amyloidosis 2, 9
• Genetic testing should be considered when clinical features suggest specific metabolic or infiltrative disorders 2

Risk Stratification and ICD Consideration

• Maximum LV wall thickness ≥30 mm is independently associated with sudden cardiac death and factors into ICD decision-making 1, 3
• Additional risk factors include family history of sudden death, unexplained syncope, non-sustained VT on ambulatory monitoring, and abnormal BP response to exercise 1

Follow-up Strategy

• Serial echocardiography should not be performed more frequently than every 12 months unless clinical changes occur that would impact decision-making 3
• Monitoring for development of atrial fibrillation, which increases stroke risk and requires anticoagulation, is essential 1
• Reassessing symptoms and functional status regularly is crucial, as progression from non-obstructive to obstructive physiology can occur 1, 4